EDIT vs EXPE · rev $32.3M vs P/E 20, rev $13.69B
Editas Medicine Inc (EDIT) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EXPE revenue for 2024-12-31 was $13.69B. Net income was $1.22B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
EDIT currently screens at market cap $375.2M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the EDIT and EXPE stock pages for the full models.
Not investment advice.